Patents by Inventor Charlotte A. Kensil

Charlotte A. Kensil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8808692
    Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: August 19, 2014
    Assignee: CSL Limited
    Inventor: Charlotte A. Kensil
  • Publication number: 20110064749
    Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.
    Type: Application
    Filed: November 18, 2010
    Publication date: March 17, 2011
    Inventor: Charlotte A. Kensil
  • Patent number: 7858589
    Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: December 28, 2010
    Assignee: Antigenics Inc.
    Inventor: Charlotte A. Kensil
  • Publication number: 20060210555
    Abstract: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and/or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.
    Type: Application
    Filed: December 20, 2002
    Publication date: September 21, 2006
    Applicant: Antigenics, Inc.
    Inventor: Charlotte Kensil
  • Publication number: 20060177458
    Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 10, 2006
    Inventor: Charlotte Kensil
  • Patent number: 7049302
    Abstract: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: May 23, 2006
    Assignee: Antigenics Inc.
    Inventor: Charlotte A. Kensil
  • Publication number: 20050191310
    Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.
    Type: Application
    Filed: October 3, 2003
    Publication date: September 1, 2005
    Inventors: Charlotte Kensil, Gerald Beltz
  • Patent number: 6645495
    Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: November 11, 2003
    Assignee: Antigenics, Inc.
    Inventors: Charlotte A. Kensil, Gerald A. Beltz
  • Patent number: 6524584
    Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: February 25, 2003
    Assignee: Antigenics, Inc.
    Inventor: Charlotte A. Kensil
  • Publication number: 20020044940
    Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.
    Type: Application
    Filed: May 14, 2001
    Publication date: April 18, 2002
    Inventor: Charlotte A. Kensil
  • Publication number: 20020044951
    Abstract: Nonpeptide antigens were isolated and purified from Mycobacterium tuberculosis. The antigens were used in vaccine compositions, pharmaceutical compositions and methods to elicit an immune response to Mycobacterium tuberculosis in a mammal.
    Type: Application
    Filed: April 4, 2001
    Publication date: April 18, 2002
    Inventors: Gui Liu, Gerald Beltz, Kenneth LeClair, Daniel Cox, Charlotte Kensil
  • Publication number: 20010034330
    Abstract: Compositions comprising oligonucleotides comprising at least one unmethylated CpG dinucleotide and saponin and the use thereof for stimulating innate immunity and enhancing natural killer cell activity are disclosed.
    Type: Application
    Filed: January 12, 2001
    Publication date: October 25, 2001
    Inventor: Charlotte Kensil
  • Patent number: 6231859
    Abstract: The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines.
    Type: Grant
    Filed: December 2, 1997
    Date of Patent: May 15, 2001
    Assignee: Aquila Biopharmaceuticals, Inc.
    Inventor: Charlotte A. Kensil
  • Patent number: 5650398
    Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 22, 1997
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani, Joanne Recchia
  • Patent number: 5583112
    Abstract: Saponin/antigen conjugates and the use thereof for enhancing immune responses in individuals are disclosed. The saponins may be substantially pure or mixtures of saponins.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: December 10, 1996
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
  • Patent number: 5443829
    Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: August 22, 1995
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
  • Patent number: 5352449
    Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.
    Type: Grant
    Filed: April 14, 1992
    Date of Patent: October 4, 1994
    Assignee: Cambridge Biotech Corporation
    Inventors: Gerald A. Beltz, Dante J. Marciani, Chung-Ho Hung, Charlotte A. Kensil
  • Patent number: 5273965
    Abstract: Methods for enhancing the transport of pharmacologically active substances across mucous membranes of an animal by administration of pharmaceutical compositions comprising modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract. Also disclosed are modified saponins having reduced irritability wherein the fatty acid moiety is removed by hydrolysis or the aldehyde group is reduced. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: December 28, 1993
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
  • Patent number: 5057540
    Abstract: Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.
    Type: Grant
    Filed: August 27, 1990
    Date of Patent: October 15, 1991
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Dante J. Marciani